bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.
bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.
The event organizers are asking guests to help raise money for two selected charities: “Cooley’s Anemia Foundation” which funds medical research and education to benefit individuals living with the genetic blood disorder, thalassemia, and “A Chance in Life -The Village of Staten Island Program,” a US-based program in New York City for forgotten youth dedicated to providing shelter, education, and leadership development for at-risk youth.
This week’s spotlight is all about Team Ficarra. Talk about longevity – the Ficarra family is one of the founders of the Cooley’s Anemia Foundation!
Fellowships
The Spotlight is on Maria Saradpon’s Team CAF California, who shares her top tips to fundraising success.
The StL Thal Pals walk in, you guessed it, St Louis, Missouri! Erica Stick is the Care Walk Captain and this is how she put her walk together. “I was lucky enough to get to know so many amazing people in the thalassemia community in my previous job,” says Erica. “Working with them daily really […]
Meet Yasmeen Anis. Yasmeen Care Walks because she has thalassemia and she wants to fundraise toward a cure! Her team has been Care Walking in Spring Hill, Florida since 2018. Yasmeen first got involved with Care Walk by joining a friend’s team and participating virtually from another state. She then decided to start her own […]
April 23, 2022 – History was made today at the annual board meeting of the Cooley’s Anemia Foundation (CAF) when Ralph Colasanti was elected the first person with thalassemia to serve as National President of the Foundation’s board of directors. The Foundation, which was started in 1954, is the primary voice for those with thalassemia, […]
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of betibeglogene autotemcel (Zynteglo/LentiGlobin, bluebird bio) for the treatment of beta thalassemia. An FDA decision on betibeglogene autotemcel is expected in mid-2022. ICER is inviting public comment on its initial Draft Scoping Document, which details […]